Business

Announcement on Voluntary Disclosure of the IND Application for the Phase III Clinical Trial of BL-M14D1 (DLL3 ADC) in Combination with Immunotherapy for First-Line Extensive-Stage Small Cell Lung Cancer Receiving FDA Clearance

Announcement on Voluntary Disclosure of the IND Application for the Phase III Clinical Trial of BL-M14D1 (DLL3 ADC) in Combination with Immunotherapy for First-Line Extensive-Stage Small Cell Lung Cancer Receiving FDA Clearance

articleSichuan Biokin Pharmaceutical Co., Ltd. Class AJune 8, 20264/news/announcement-on-voluntary-disclosure-of-the-ind-application-for-the-phase-iii-clinical-trial-of-bl-m14d1-dll3-adc-in-combination-with-immunotherapy-for-first-line-extensive-stage-small-cell-lung-cancer-receiving-fda-clearance
Announcement on Voluntary Disclosure of the IND Application for the Phase III Clinical Trial of BL-M14D1 (DLL3 ADC) in Combination with Immunotherapy for First-Line Extensive-Stage Small Cell Lung Cancer Receiving FDA Clearance

About this update from Sichuan Biokin Pharmaceutical Co., Ltd. Class A

Announcement on Voluntary Disclosure of the IND Application for the Phase III Clinical Trial of BL-M14D1 (DLL3 ADC) in Combination with Immunotherapy for First-Line Extensive-Stage Small Cell Lung Cancer Receiving FDA Clearance The abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Sichuan Biokin Pharmaceutical Co., Ltd. Class A